AUPH could cut their asking price significantly ( apparently this is not an expensive drug to make ) and make $ thru higher volume ....but so far have apparently chosen not to follow that path
Maybe their internal research and projections do not support the "higher volume" thesis. I would think they're best qualified to make that judgement.